Fig. 6

BMP4 reprograms hepatic glycogen accumulation and promotes tumor growth in vivo. A 1 μm BAY-876 or equal volume DMSO was used to treated Huh7 and HepG2 cells, and Western blot was used to analyze the expression of BMP4, SLC2A1, SMAD5, and p-SMAD5 in Huh7 and HepG2 cells after 72 h. B Huh7 cells were infected with Ad-B4 or Ad-GFP and subcutaneously injected into the flanks of athymic nude mice. The mice in Ad-B4 + BAY-876 group were administered through gavage with BAY-876, and the mice in Ad-B4 group and Ad-GFP group were administered through gavage with equal volume CMC. The average tumor volume was assessed from weeks 1 to 4 successively. **P < 0.01, ^##P < 0.01, Ad-B4 group vs Ad-GFP group, Ad-B4 + BAY-876 group vs Ad-GFP group. C The size of subcutaneous tumor after 28 days of 6A. D The average tumor weight was assessed of 6A. **P < 0.01, ^##P < 0.01, Ad-B4 group vs Ad-GFP group, Ad-B4 + BAY-876 group vs Ad-GFP group. E H & E, PAS, and IHC staining were used to check the morphology, glycogen accumulation, and the expression of BMP4, SLC2A1, SMAD5, and p-SMAD5 in Hu7 cells in vivo of B